TNSN05319A1 - DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS - Google Patents

DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS

Info

Publication number
TNSN05319A1
TNSN05319A1 TNP2005000319A TNSN05319A TNSN05319A1 TN SN05319 A1 TNSN05319 A1 TN SN05319A1 TN P2005000319 A TNP2005000319 A TN P2005000319A TN SN05319 A TNSN05319 A TN SN05319A TN SN05319 A1 TNSN05319 A1 TN SN05319A1
Authority
TN
Tunisia
Prior art keywords
une
azithromycine
orale
comprenant
agent
Prior art date
Application number
TNP2005000319A
Other languages
French (fr)
Inventor
Timothy Arthur Hagen
Scott Max Herbig
Julian Belknap Lo
Avinash Govind Thombre
Leah Elizabeth Appel
Marshall David Crew
Dwayne Thomas 7Friesen
David Keith Lyon
Scott Baldwin Mccray
James Blair West
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2004/001654 external-priority patent/WO2005053650A1/en
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN05319A1 publication Critical patent/TNSN05319A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Une forme posologique orale comprenant de l'azithromycine et une quantité efficace d'un agent alcanilisant. De préférence, ladite forme posologique orale comprend une quantité efficace d'un agent alcalinisant et une forme en particules multiples d'azithromycine, ladite forme en particules multiples comprenant de l'azithromycine, un mélange de monobéhénate de glycéryle, de dibéhénate de glycéryle et de tribéhénate de glycéryle, et un poloxamère. Habituellement, la forme posologique orale comprend n'importe quel moyen d'administration orale convenable tel qu'une poudre pour suspension orale, un paquet ou sachet de dose unitaire, un comprimé ou une capsule. Il est révélé en outre une suspension orale comprenant de l'azithromycine, une quantité efficace d'un agent alcalinisant et un véhicule. De préférence, l'azithromycine est une forme en particules multiples dans laquelle lesdites particules multiples comprennent de l'azithromycine, un mélange de monobéhénate de glycéryle, de dibéhénate de glycéryle et de tribéhénate de glycéryle, et un poloxamère. Il est révélé également une méthode pour réduire les effets secondaires gastro-intestinaux, associés à l'administration d'azithromycine à un mammifère, comprenant l'administration de manière contiguë d'azithromycine et d'une quantité efficace d'un agent alcalinisant audit mammifère, la fréquence des effets secondaires gastro-intestinaux étant inférieur à celle constatée en administrant une dose égale d'azithromycine sans ledit agent alcalinisant. Il est révélé en outre une méthode pour le traitement d'une infection par des bactéries ou des protozoaires chez un mammifère nécessitant un tel traitement, comprenant l'administration de manière contiguë audit mammifère d'une dose unique d'une forme posologique orale, ladite forme posologique orale, comprenant de l'azithromycine et une quantité efficace d'un agent alcalinisant. Il est révélé en outre une forme en particules multiples d'azithromycine comprenant de l'azithromycine, un agent tensio-actif et un support pharmaceutiquement acceptable.
TNP2005000319A 2003-12-04 2005-12-14 DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS TNSN05319A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52708403P 2003-12-04 2003-12-04
PCT/IB2004/001654 WO2005053650A1 (en) 2003-12-04 2004-05-14 Azithromycin dosage forms with reduced side effects

Publications (1)

Publication Number Publication Date
TNSN05319A1 true TNSN05319A1 (en) 2007-07-10

Family

ID=34699855

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2005000319A TNSN05319A1 (en) 2003-12-04 2005-12-14 DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS

Country Status (8)

Country Link
CN (1) CN1697648B (en)
AP (1) AP2218A (en)
AU (1) AU2004216676B2 (en)
EC (1) ECSP045351A (en)
GT (1) GT200400183A (en)
TN (1) TNSN05319A1 (en)
UA (1) UA78793C2 (en)
ZA (1) ZA200408075B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101340882B (en) * 2005-12-22 2015-02-11 大塚制药株式会社 Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
CN103054813A (en) * 2012-12-31 2013-04-24 广东先强药业有限公司 Azithromycin oral sustained-release dry suspension and preparation method thereof
CN104177457A (en) * 2013-05-23 2014-12-03 长春海悦药业有限公司 Azithromycin drug raw material, and preparation and application thereof
EP3267997A4 (en) * 2015-03-10 2018-08-15 Lumos Pharma, Inc. Cyclocreatine microsuspension
AU2018216185B2 (en) * 2017-02-02 2023-08-03 Mcmaster University Bicarbonate as a potentiator for antimicrobial agents
CN114213484A (en) * 2021-12-21 2022-03-22 河北远征药业有限公司 Tildipirosin 1, 2-propylene glycol solvent compound and preparation method thereof
CN115212173B (en) * 2022-07-11 2024-10-15 上海现代药物制剂工程研究中心有限公司 Ambroxol hydrochloride spherical slow-release particles, preparation method and application

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW271400B (en) * 1992-07-30 1996-03-01 Pfizer
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
CN1123279A (en) * 1995-06-15 1996-05-29 沈家祥 Azithmycin water-soluble salt, injection thereof and their usage
EP1478347A1 (en) * 2002-02-01 2004-11-24 Pfizer Products Inc. Dry granulated formulations of azithromycin

Also Published As

Publication number Publication date
CN1697648B (en) 2010-06-23
CN1697648A (en) 2005-11-16
GT200400183A (en) 2005-10-24
AP2004003145A0 (en) 2004-09-30
AU2004216676A1 (en) 2005-06-23
ECSP045351A (en) 2005-01-28
AP2218A (en) 2011-04-20
ZA200408075B (en) 2007-01-31
AU2004216676B2 (en) 2011-06-16
UA78793C2 (en) 2007-04-25

Similar Documents

Publication Publication Date Title
MA27848A1 (en) DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS.
TNSN05319A1 (en) DOSAGE FORMS OF AZITHROMYCIN WITH REDUCED SIDE EFFECTS
US5614560A (en) Method of preventing NMDA receptor-mediated neuronal damage
MA29564B1 (en) FORMULATION OF 1 - [(3-HYDROXY-ADAMANT-1-YLAMINO) -ACETYL] -PYRROLIDINE-2 (S) -CARBONITRILE
FI97689B (en) A method for stabilizing an aqueous mixture of a heterocyclic compound
MA27927A1 (en) PHARMACEUTICAL PREPARATIONS
MA29744B1 (en) SOLID DOSAGE FORMULATIONS OF MEDICAMENTS HAVING IMPROVED ORAL ADSORPTION
EP1879656B1 (en) Pharmaceutical composition comprising an antitumoral agent and an active agent selected especially among carveol, thymol and carvacrol
Marini et al. The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells
JP2017095474A (en) Stable povidone-iodine compositions with steroids or non-steroidal anti-inflammatory drugs
US6667329B1 (en) Agents with antidepressant action, containing pramipexol and second antidepressant
LU87202A1 (en) USE OF CERTAIN 17-CETOSTEROIDS, POSSIBLY WITH AN IMMUNO-MODULATOR AND / OR ANTIVIRAL AGENT, TO MANUFACTURE A MEDICAMENT FOR THE TREATMENT AND PREVENTION OF RETROVIRAL INFECTIONS
CR6458A (en) VALDECOXIB COMPOSITIONS
MA27729A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR AGONIST AND SUGAR ALCOHOL
TNSN08152A1 (en) PROLONGED RELEASE COMPOSITION OF THE ACTIVE INGREDIENTS, PROCESS FOR PREPARING THE SAME AND USE THEREOF
KR20060109493A (en) Combination drug therapy to treat obesity
US6815461B1 (en) Method of inhibiting retroviral integrase
DE60022895D1 (en) PDGF-RECEPTOR-KINASE-INHIBITABLE COMPOUNDS, THE PREPARATION, CLEANING AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS
Hiraoka et al. Effects of polyethylene glycol conjugated superoxide dismutase on coxsackievirus B3 myocarditis in mice
TNSN05054A1 (en) BETA-LACTAMASE INHIBITOR DRUG PRECURSOR
HRP960271A2 (en) Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
KR101686917B1 (en) Pharmaceutical composition comprising racetam and carnitine and process for its preparation
KR930007252B1 (en) Pharmaceutical composition for treatment of depression
ZA200507322B (en) Selective cytokine inhibitory drugs for treating disorders of the central nervous system
Tenenbaum et al. Secnidazole concentrations in plasma and crevicular fluid after a single oral dose